目的 考察抗表皮生长因子受体全人单克隆抗体Ranti-HER单用及联合用药对裸鼠人癌移植瘤的抑制作用,探讨其抑制作用是否与表皮生长因子受体(epidermal growth factor receptor, EGFR)表达有关。方法 采用流式细胞术定性人源肿瘤细胞EGFR的表达程度,建立人源肿瘤细胞裸鼠皮下移植瘤模型,然后分组给药,以相对肿瘤增值率评估其抗肿瘤有效性。结果 人鳞状细胞癌A431细胞为EGFR高表达细胞,人结肠癌HT29和SW948细胞对EGFR低表达,人结肠癌SW620细胞对EGFR为阴性表达。给予不同剂量Ranti-HER(0.25、0.5、1 mg·只-1,biw×3)能显著抑制A431移植瘤的生长,并表现出一定的剂量相关性;与多柔比星(125 μg·只-1,qd×2)合用后呈现联合抗肿瘤作用。Ranti-HER 1.0 mg(biw×3)能明显延缓SW948移植瘤的生长,与伊立替康联合应用,抑制肿瘤生长作用表现出相加的趋势。对于HT29和SW620移植瘤,Ranti-HER 1.0 mg(biw×3)未见明显抑瘤作用。结论 Ranti-HER单独应用能抑制裸鼠人癌移植瘤的生长,其抑制作用与EGFR的表达水平有一定相关性,Ranti-HER与其他化疗药物联合应用,具有协同抗肿瘤作用。
Abstract
OBJECTIVE To observe the in vivo activity of Ranti-HER, a fully human monoclonal antibody, and combined with the doxorubicin or CPT-11 in established human tumor xenografts in nude mice, and to investigate whether EGFR expression is correlated with this activity. METHODS The overall receptor of EGF was quantified by flow cytometry. The anti-tumor effects of Ranti-HER were evaluated using established, s/c human carcinoma xenografts in nude mice, and the relative growth rate of tumor was used to assess the anti-tumor activity. RESULTS A431 cells showed highly expression of EGFR by flow cytometry, SW620 showed negative expression, and EGFR were expressed positively in HT29 and SW948 cells, but both of them were showed low expression. Ranti-HER(0.25-1.0 mg) could inhibit the tumor growth in human A431 epidermoid carcinoma xenografts and dose-effect relationship was observed; Ranti-HER(1.0 mg) could also inhibit the tumor growth in human SW948 colon carcinoma xenografts, but no anti-tumor effects of Ranti-HER 1.0 mg were observed in human HT29 and SW620 colon carcinoma xenografts. Therapeutic enhancement was observed in the A431 xenografts after treatment with Ranti-HER combined with doxorubicin. For another combination regimens, Ranti-HER and CPT-11 proved to be significantly more efficacious than Ranti-HER monotherpy in SW948 xenografts. CONCLUSION Anti-tumor activity of Ranti-HER are observed in xenografts in athymic nude mice, and the activity of Ranti-HER is correlated with the EGFR expression; synergistic effects are observed when Ranti-HER is combined with chemicals compared to Ranti-HER monotherapy.
关键词
全人源单克隆抗体 /
Ranti-HER /
表皮生长因子受体 /
抗肿瘤作用
{{custom_keyword}} /
Key words
fully human monoclonal antibody /
Ranti-HER /
epidermal growth factor receptor /
anti-tumor activity
{{custom_keyword}} /
中图分类号：
R969
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] CASTILLO L, ETIENNE-GRIMALDI M C, FISCHEL J L, et al. Pharmacological background of EGFR targeting [J]. Ann Oncol, 2004, 15(7):1007-1012.
[2] ARTEAGA C. Targeting HER1/EGFR: a molecular approach to cancer therapy [J]. Semin Oncol, 2003, 30(3 Suppl 7):3-14.
[3] MENDELSOHN J, BASELGA J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer [J]. J Clin Oncol, 2003,21(14):2787-2799.
[4] SKVORTSOV S, SARG B, LOEFFLER-RAGG J, et al. Different proteome pattern of epidermal growth factor receptor-positive colorectal cancer cell lines that are responsive and nonresponsive to C225 antibody treatment [J]. Mol Cancer Ther, 2004, 3(12):1551-1558.
[5] XU H, YU Y, MARCINIAK D, et al. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells[J]. Mol Cancer Ther, 2005,4(3):435-442.
[6] LONARDO F, DRAGNEV K H, FREEMANTLE S J, et al. Evidence for the epidermal growth factor receptor as a target for lung cancer prevention [J]. Clin Cancer Res, 2002,8(1):54-60.
[7] CARPENTER R L, JIANG B H. Roles of EGFR, PI3K, AKT, and mTOR in heavy metal-induced cancer [J]. Curr Cancer Drug Targets, 2013,13(3):252-266.
[8] AMANN J, KALYANKRISHNA S, MASSION P P, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer [J]. Cancer Res, 2005, 65(1):226-235.
[9] KHAZAELI M B, LOBUGLIO A F, FALCEY J W, et al. Low immunogenicity of a chimeric monoclonal antibody (MOAB), IMC-C225, used to treat epidermal growth factor receptor 2 positive tumors [J]. Proc Am Soc Clin Oncol, 2000, 19:207.
[10] YANG E B, GUO Y J, ZHANG K, et al. Inhibition of epidermal growth factor receptor tyrosine kinase by chalcone derivatives [J]. Biochim Biophys Acta, 2001,1550(2):144-152.
[11] CROMBET-RAMOS T, RAK J, PéREZ R, et al. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: a humanized anti-EGFR antibody [J]. Int J Cancer, 2002,101(6):567-575.
[12] AMADOR M L, OPPENHEIMER D, PEREA S, et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors [J]. Cancer Res, 2004, 64(24):9139-9143.
[13] CIARDIELLO F, TORTORA G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor [J]. Clin Cancer Res, 2001, 7(10):2958-2970.
[14] PREWETT M C, HOOPER A T, BASSI R, et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts [J]. Clin Cancer Res, 2002, 8(5):994-1003.
[15] FAN J H, ZHAO J Y, CHENG G X. Advances in EGFR monoclonal antibody and tumor therapy [J]. Chin J Cancer Biother (中国肿瘤生物治疗杂志), 2003, 10(3):221-222.
[16] ROTHENBERG M L, COX J V, DEVORE R F, et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma [J]. Cancer, 1999,85(4):786-795.
[17] SALTZ L B, COX J V, BLANKE C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group [J]. N Engl J Med, 2000, 343(13):905-914.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
国家“重大新药创制”科技重大专项(2012ZX09302-001)
{{custom_fund}}
PDF(2867 KB)
